Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 20/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.53 |
| ▸ | JAK1 | P23458 | 5/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31197211 | 0.87 | TYK2 (0.54) | TYK2JAK2JAK1KCNH2 | |
| SCHEMBL20073649 | 0.87 | TYK2 (0.51) | TYK2JAK2JAK1KCNH2STAT3 | |
| SCHEMBL26045961 | 0.85 | TYK2 (0.49) | TYK2JAK2JAK1KCNH2 | |
| SCHEMBL22906050 | 0.85 | JAK2 (0.51) | TYK2JAK2JAK1KCNH2 | |
| SCHEMBL17194889 | 0.82 | TYK2 (0.45) | TYK2JAK2JAK1KCNH2 | |
| SCHEMBL28432470 | 0.81 | TYK2 (0.51) | TYK2JAK2JAK1KCNH2STAT3 | |
| SCHEMBL28896991 | 0.81 | TYK2 (0.50) | TYK2JAK2JAK1KCNH2 | |
| SCHEMBL29039323 | 0.81 | TYK2 (0.44) | TYK2JAK2JAK1KCNH2STAT3 | |
| SCHEMBL24288086 | 0.79 | TYK2 (0.45) | TYK2JAK2JAK1KCNH2 | |
| SCHEMBL15690539 | 0.79 | TYK2 (0.45) | TYK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109120-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-11220508-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11174265-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
| US-20210206748-A1 | CRYSTALLINE FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE | BRISTOL MYERS SQUIBB CO (US) | 2021-07-08 | — | — | US | disclosed |
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | ESKER THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2021011513-A1 | PRODRUGS IN THE MODULATION OF INTERLEUKIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2020-11-12 | — | — | US | disclosed |
| WO-2020159904-A1 | AMIDE-DISUBSTITUTED PYRIDINE OR PYRIDAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220508-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TYK2 1/4885JAK2 2/4885JAK1 3/4885 |
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | TYK2, JAK1, PDXK | TYK2 1/4885JAK2 5/4885JAK1 2/4885 |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | TYK2, JAK1, PDXK | TYK2 1/4885JAK2 4/4885JAK1 2/4885 |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | TYK2 1/4885JAK2 3/4885JAK1 2/4885 |
| US-11174265-B2 | — | TYK2, JAK2, JAK1 | TYK2 1/4885JAK2 2/4885JAK1 3/4885 |
| US-20210206748-A1 | CRYSTALLINE FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TUBA3C, H1-3 | TYK2 703/4885JAK2 3077/4885JAK1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.